Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News

 

Venture Capital Database 2014 Now Available

GTCR Announces Partnership With Carl Hull and Eric Tardif to Form Maravai Life Sciences

CHICAGO, March 18, 2014-- GTCR, a leading private equity firm, today announced that it has entered into a partnership with Carl Hull and Eric Tardif to form Maravai Life Sciences, Inc. (“Maravai”). The new company, headquartered in San Diego, California, will focus on acquiring companies and products in the diagnostics and life sciences industry as part of a strategy to build a market leading healthcare business. GTCR will invest up to $300 million of equity capital to support management's strategy.

Mr. Hull is a thirty-year veteran of the diagnostic and life sciences industry. Prior to partnering with GTCR, Mr. Hull was Chief Executive Officer of Gen-Probe, a market leading molecular diagnostic company. While at Gen-Probe, Mr. Hull led a strategic transformation that focused the company’s resources on its core growth areas of clinical diagnostics and laboratory automation. His leadership helped reposition the business for commercial growth, culminating in the eventual sale of Gen-Probe to Hologic for $3.7 billion. Prior to his time at Gen-Probe, he held a number of executive roles at various diagnostics and life sciences companies, including Applied Biosystems, Ventana Medical Systems and Abbott Laboratories.

Eric Tardif joined Mr. Hull at Gen-Probe as Senior Vice President after spending over a decade covering life sciences clients at Morgan Stanley and other firms. At Gen-Probe, Mr. Tardif was responsible for establishing corporate strategy, evaluating and executing all mergers and acquisitions, including Gen-Probe’s sale to Hologic, and leading the integration efforts for the acquired companies.

“We are very excited to partner with Carl and Eric to build a leading company in the diagnostics and life sciences industry,” said GTCR Managing Director Dean Mihas. “They have exceptional track records of thoughtful leadership and value creation. Their expertise, strategic vision and operational abilities make them ideal partners as GTCR commits to a platform in this attractive industry.”

“I am thrilled about the opportunity to work with GTCR to build Maravai into an industry leader in the diagnostics and life sciences space,” said Mr. Hull. “The firm has a long history of backing experienced CEOs and providing them with the resources and support to build successful companies through both organic growth and acquisitions. GTCR has been actively evaluating opportunities and developing a unique expertise in diagnostics and life sciences. With our partnership, Maravai is well positioned to benefit from the firm’s deep domain knowledge and expertise.”

“GTCR’s formation of Maravai demonstrates our interest in investing additional capital in a dynamic and growing segment of healthcare,” added Ben Daverman, Vice President at GTCR. “We are actively looking for acquisitions and believe there will continue to be a number of compelling investment opportunities in the market. Working with Maravai, we are in a unique position to evaluate and pursue these investments.”

GTCR’s investment in Maravai will be made from GTCR Fund X LP, a private equity fund with $3.25 billion of equity capital commitments.

About GTCR

Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.

About Maravai Life Sciences

Maravai Life Sciences was formed in March 2014 as a partnership between Carl Hull and Eric Tardif and GTCR. Maravai’s mission is to build a transformative company in the in vitro diagnostics and life sciences tools markets by acquiring outstanding businesses in these spaces and accelerating their growth. For more information about Maravai Life Sciences, please contact (312) 953-3305 or visit www.maravai.com.

Contact:
GTCR
Eileen Rochfod, 312-953-3305


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools

 

 

Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer